1 menahydroquinone-4 prodrug: a promising candidate anti-hepatocellular carcinoma agent

2 hemorrhagic disease of newborns with late debut

3 CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects

4 Turn-on type chemical sensing of vitamin K4 by fluorene dendrimers with naphthalene segments.

5 Prothrombin Complex Concentrates are Superior to Fresh Frozen Plasma for Emergency Reversal of Vitamin K Antagonists: A Meta-Analysis in 2606 Subjects.

6 Non-vitamin K oral anticoagulants versus warfarin for left atrial appendage thrombus resolution in nonvalvular atrial fibrillation or flutter.

7 Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation.

8 Long-Term Vitamin K Antagonists and Cancer Risk: A Systematic Review and Meta-Analysis.

9 Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in secondary stroke and systemic embolism prevention.

10 Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.

11 Novel anticoagulants versus vitamin K antagonists for cardioversion of non- valvular atrial fibrillation – a meta-analysis of more than 17000 patients

12 Effect of vitamin K on bone mineral density and fractures in adults: an updated systematic review and meta-analysis of randomised controlled trials

13 Corrigendum to “Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis” [Arch. Gerontol. Geriatr. 81 (March–April)(2019)209–214](S0167494318302450)(10.1016/j.archger.2018.12.013)

14 Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation: a Systematic Review and Meta-analysis

15 Net clinical benefit analysis of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: Protocol for a systematic review and meta-analysis

16 Low-intensity anti-coagulation using Vitamin K antagonists and Factor X activity: A validation analysis of the MAGENTUM-1 study

17 Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis

18 Vitamin K status, supplementation and vascular disease: A systematic review and meta-analysis

19 Efficacy and safety of reduced-dose non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation: A meta-analysis of randomized controlled trials

20 Efficacy and safety of prothrombin complex concentrate for vitamin K antagonist-associated intracranial hemorrhage: a systematic review and meta-analysis

21 The relationship between dietary vitamin k and depressive symptoms in late adulthood: A cross-sectional analysis from a large cohort study

22 Economic evaluation of the use of non-Vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: A modelling analysis using the healthcare system in the Netherlands

23 Outcomes of intraparenchymal hemorrhage after direct oral anticoagulant or vitamin K antagonist therapy: A systematic review and meta-analysis

24 Use of vitamin K antagonists and risk of prostate cancer: Meta–analysis and nationwide case–control study

25 Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis

26 Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis

27 Non-vitamin K oral anticoagulants in nonvalvular atrial fibrillation: a network meta-analysis

28 Vitamin K status and cardiovascular events or mortality: A meta-analysis

29 Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis

30 A Systematic Review and Meta-analysis of the Association Between Vitamin K Antagonist Use and Fracture

31 Comment on “Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis”

32 Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies

33 Efficacy and Safety of the Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Ischemic Heart Disease: A Meta-Analysis of Phase III Randomized Trials

34 Decreased risk of renal impairment in atrial fibrillation patients receiving non-vitamin K antagonist oral anticoagulants: A pooled analysis of randomized controlled trials and real-world studies

35 DOACs vs Vitamin K Antagonists: a Comparison of Phase III Clinical Trials and a Prescriber Support Tool

36 Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients

37 Effect of vitamin K on bone mineral density and fractures in adults: an updated systematic review and meta-analysis of randomised controlled trials

38 Biofilm reactors as a promising method for vitamin K (menaquinone-7) production.

39 A Case Report of Intraoperative Coagulopathy Secondary to Chronic Vitamin K Deficiency.

40 Mechanisms of PKC-Mediated Enhancement of HIF-1α Activity and its Inhibition by Vitamin K2 in Hepatocellular Carcinoma Cells.

41 The Contribution of Lipids to the Inter-Individual Response of Vitamin K Biomarkers to Vitamin K Supplementation.

42 New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients.

43 Vitamin K antagonist rodenticides display different teratogenic activity.

44 Does the CHA2DS2-VASc scale sufficiently predict the risk of left atrial appendage thrombus in patients with diagnosed atrial fibrillation treated with non-vitamin K oral anticoagulants?

45 Reduced vitamin K status as a potentially modifiable risk factor of severe COVID-19

46 prolonged survival in a case of chemotherapy-sensitive gastric cancer that produced alpha-fetoprotein and protein induced by vitamin k antagonist-ii

47 non-vitamin k antagonist oral anticoagulants vs. warfarin at risk of fractures: a systematic review and meta-analysis of randomized controlled trials

48 hematoma subdural de medula espinhal associada ao uso de anticoagulante oral hematoma subdural de la médula espinal asociado al uso de anticoagulante oral spine subdural hematoma: a rare complication associated with vitamin k antagonist (vka)

49 vitamin k: the effect on health beyond coagulation – an overview

50 perfil bioquímico e nutricional do ácido glutâmico e da vitamina k no soro e no fígado de frangos de corte de 1 a 21 dias de idade biochemical and nutritional profile of glutamic acid and vitamin k in serum and liver of broilers from 1 to 21 days

51 nonvitamin k antagonist oral anticoagulants (noacs): the tide continues to come in

52 cumarinas, interacción con anticoagulantes antagonistas de la vitamina k y seguridad del haba tonka coumarins: interaction with vitamin k antagonists and safety of tonka bean

53 acquired vitamin k deficiency as unusual cause of bleeding tendency in adults: a case report of a nonhospitalized student presenting with severe menorrhagia

54 Non-vitamin K oral anticoagulants and risk of fractures: a systematic review and meta-analysis.

55 Effects of vitamin K1 and prednisolone on the blood coagulation in liver disease

56 Effects of vitamin K2 and chlorogenic acid on bone metabolism in postmenopausal rats with iron overload

Keyword Connections

Journals

Research Groups

Bibliographies